We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Inter-individual differences in CpG methylation at D4Z4 correlate with clinical variability in FSHD1 and FSHD2.
- Authors
Lemmers, Richard J.L.F.; Goeman, Jelle J.; van der Vliet, Patrick J.; van Nieuwenhuizen, Merlijn P.; Balog, Judit; Vos-Versteeg, Marianne; Camano, Pilar; Ramos Arroyo, Maria Antonia; Jerico, Ivonne; Rogers, Mark T.; Miller, Daniel G.; Upadhyaya, Meena; Verschuuren, Jan J.G.M.; de Munain Arregui, Adolfo Lopez; van Engelen, Baziel G.M.; Padberg, George W.; Sacconi, Sabrina; Tawil, Rabi; Tapscott, Stephen J.; Bakker, Bert
- Abstract
Facioscapulohumeral muscular dystrophy (FSHD: MIM#158900) is a common myopathy with marked but largely unexplained clinical inter- and intra-familial variability. It is caused by contractions of the D4Z4 repeat array on chromosome 4 to 1–10 units (FSHD1), or by mutations in the D4Z4-binding chromatin modifier SMCHD1 (FSHD2). Both situations lead to a partial opening of the D4Z4 chromatin structure and transcription of D4Z4- encoded polyadenylated DUX4 mRNA in muscle. We measured D4Z4 CpG methylation in control, FSHD1 and FSHD2 individuals and found a significant correlation with the D4Z4 repeat array size. After correction for repeat array size,weshowthat the variability in clinical severity inFSHD1and FSHD2individuals is dependent on individual differences in susceptibility toD4Z4 hypomethylation. InFSHD1, for individuals with D4Z4 repeat arrays of 1–6 units, the clinical severitymainly depends on the size of the D4Z4 repeat.However, in individuals with arrays of 7– 10 units, the clinical severity also depends on other factors that regulate D4Z4methylation because affected individuals, but not non-penetrant mutation carriers, have a greater reduction of D4Z4 CpG methylation than can be expected based on the size of the pathogenic D4Z4 repeat array. In FSHD2, this epigenetic susceptibility depends on the nature of the SMCHD1mutation in combination with D4Z4 repeat array size with dominant negativemutations being more deleterious than haploinsufficiency mutations. Our study thus identifies an epigenetic basis for the striking variability in onset and disease progression that is considered a clinical hallmark of FSHD.
- Publication
Human Molecular Genetics, 2015, Vol 24, Issue 3, p659
- ISSN
0964-6906
- Publication type
Article
- DOI
10.1093/hmg/ddu486